Perspectives on the development of a therapeutic HER-2 cancer vaccine (Q36880984)

16 August 2017

1 reference

title

Perspectives on the development of a therapeutic HER-2 cancer vaccine (English)

1 reference

16 August 2017

Valéry Renard

1

1 reference

16 August 2017

Dana R Leach

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

18 June 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

25 Suppl 2

1 reference

16 August 2017

page(s)

B17-23

1 reference

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Progress and new standards of care in the management of HER-2 positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Generation of autoreactive CTL by tumour vaccines containing foreign T helper epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Linked foreign T-cell help activates self-reactive CTL and inhibits tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Therapeutic antibodies elicited by immunization against TNF-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

Structure/function studies on QS-21, a unique immunological adjuvant from Quillaja saponaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.060

10.1016/J.VACCINE.2007.05.060

7 January 2021

Identifiers

DOI

1 reference

16 August 2017

1 reference